Bristol-Myers Squibb completes previously announced acquisition of IFM Therapeutics
Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has completed the previously announced planned acquisition of IFM Therapeutics. The transaction includes full rights to IFM's preclinical STING (stimulator of interferon genes) and NLRP3 agonist programs focused on enhancing the innate immune response for treating cancer.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news
More News: Cancer | Cancer & Oncology | Genetics | Insect Bites & Stings | Mergers and Aquisitions | Pharmaceuticals